View source for PHAC Conflict of Interest Toolkit for Guideline Development

{{DISPLAYTITLE:PHAC Conflict of Interest Toolkit for Guideline Development}}

== '''Background''' ==
Clinical and public health guidelines are “systematically developed, evidence-based statements which assist providers, recipients and other stakeholders to make informed decisions about appropriate health interventions.”<ref name=":4">Institute of Medicine (US) Committee to Advise the Public Health Service on Clinical Practice Guidelines; Field MJ, Lohr KN, editors. Clinical Practice Guidelines: Directions for a New Program. Washington (DC): National Academies Press (US); 1990. Available from: https://www.ncbi.nlm.nih.gov/books/NBK235751/</ref> 

The Public Health Agency of Canada (PHAC) develops a variety of guidelines that provide advice to policy-makers, public healthcare systems, and Canadians through the support of standing guideline panels, and by providing funding or collaborating with external organizations on ad hoc topics. Topic areas for PHAC guidance include travel medicine, immunizations, influenza prevention, problematic substance use, family violence, dementia, suicide prevention, traumatic head injury/concussions, physical activity, cancer prevention, sexual health, healthcare-acquired infections, and tobacco cessation.

To maximize their impact, guidelines should be free of conflicts of interest (COI) – situations in which the judgment of an individual involved in developing a guideline is unduly influenced (or seen to be unduly influenced) by a secondary interest (such as the opportunity to derive personal benefit).<ref name=":4" />

Given several high-profile news stories within and outside Canada,<ref>Johnson L, Stricker RB. Attorney General forces Infectious Diseases Society of America to redo Lyme guidelines due to flawed development process. Journal of Medical Ethics. 2009;35:283-288.</ref><ref>Lenzer J. French guidelines are withdrawn after court finds potential bias among authors. BMJ. 2011 Jun 24;342:d4007. </ref><ref>Howlett, K. Conflicts of interest didn’t influence new opioid standards: review. The Globe and Mail [online]. September 7, 2017. Available from: https://www.theglobeandmail.com/news/national/conflicts-of-interest-didnt-influence-new-opioid-standards-review/article36199835/</ref><ref>Dwyer, D. WHO drops opioid guidelines after criticism of corporate influence. The BMJ. 2019:365. Available from: https://www.bmj.com/content/365/bmj.l4374</ref><ref>Cosgrove L, Bursztajn HJ, Erlich DR, Wheeler EE, Shaughnessy AF. Conflict of interest and clinical guidelines. J Eval Clin Pract. 2013;19: 674-681.</ref><ref>The Canadian Press. Co-author of controversial meat study did not disclose ties to ‘classic front group’. National Post. October 5, 2019. Available from: https://nationalpost.com/news/canada/scientist-responds-to-critique-of-industry-ties-after-publishing-study-on-red-meat</ref><ref>Cohen D, Brown E. Surgeons withdraw support for heart disease advice. BBC Newsnight. December 9, 2019. Available from: https://www.bbc.com/news/health-50715156.</ref> the health community that benefits from evidence-based guidance and policy, and Canadians more generally, are increasingly aware of the importance of disclosing and managing COI in guidelines. These examples demonstrate the considerable reputational and other risks that poorly managed COI in the context of guidelines could pose to PHAC and its partners. Beyond that, proper management of COI is an established criterion for assessing guideline quality.<ref>Brouwers MC, Kho ME, Browman GP, Burgers J, Cluzeau F, Feder G, Fervers B, Graham, ID, Grimshaw J, Hanna S, Littlejohns P, Makarski J, Zitzelsberger L on behalf of the AGREE Next Steps Consortium. AGREE II: Advancing guideline development, reporting and evaluation in healthcare.  Can Med Assoc J.  2010;182:E839-842.</ref> 

PHAC has taken steps towards addressing the issue of COI in guideline development by hosting a Best Brains Exchange on the topic<ref name=":5">Canadian Institutes of Health Research. Reducing and managing conflicts of interest in clinical practice guideline development: do we need Pan-Canadian standards? Government of Canada, 2019. Available from: http://www.cihr-irsc.gc.ca/e/51455.html</ref> in collaboration with CIHR. This meeting, which took place in January 2019, brought together over 60 participants representing academia, guideline producing groups from Canada and internationally, journal editors, and federal and provincial governments. 

The principles put forward by the Guidelines International Network (GIN) are a key guiding document for improving the management of COI within guideline development, and were discussed extensively at the BBE.<ref name=":5" /><ref name=":6">Schünemann HJ, Al-Ansary LA, Forland F, et al. Guidelines International Network: Principles for Disclosure of Interests and Management of Conflicts in Guidelines. Ann Intern Med. 2015;163:548–553.</ref> The GIN principles provide a framework for consistent and appropriate management of COI in guideline development.<ref name=":6" /> While there was broad agreement that implementation of these principles would improve COI management in Canadian guidelines, it was felt by many that support would be needed to fully implement these principles across various groups. 

Overall, one clear theme emerged from the BBE: The need for national leadership, national standards, national approaches, and national transparency to help bring Canada up to the level of COI management seen in other countries.<ref name=":5" /> A report summarizing the BBE presentations and discussions is available in both official languages using the following links:

[[Images/0/0b/BBE COI in CPG development EN FINAL.pdf|CIHR/PHAC Best Brains Exchange (English) - Reducing and managing conflicts of interest in clinical practice guideline development: Do we need Pan-Canadian standards?]]

[[Images/e/e1/BBE COI in CPG development FR FINAL.pdf|Échanges Meilleurs Cerveaux IRSC/ASPC (français) - Réduction et gestion des conflits d’intérêts dans l’élaboration de recommandations pour la pratique clinique : faut-il établir des normes pancanadiennes?]]

Shortly after the BBE, the Canadian Medical Association Journal, one of the foremost publishers of guidelines in Canada, announced that as of 2020, all groups publishing guidelines in their journal must adhere to the GIN principles.<ref>Kelsall D. New CMAJ policy on competing interests in guidelines. CMAJ. 2019; 191(13):E350-351. </ref> Therefore it is anticipated that a key area for national leadership in this area will be to help Canadian guideline producers (within PHAC or external) in adhering to the GIN principles, and generally implementing best practices related to COI. For some groups, this may require only small shifts in their current policies and procedures, while for other groups (e.g., smaller or with less resources) this could require considerable work. 

PHAC, through its Guidance Innovation Hub has developed a compendium of tools, listed on this page, that can be used by national guideline development groups to help improve their practices related to the management of COI, including adherence to the GIN principles.


== Guidelines International Network (GIN) checklist ==
The following checklist was developed by PHAC to aid journals seeking to implement the GIN principles on COI for authors, or guideline developers assessing or updating their policies to align with the GIN principles.

A link to the document will be uploaded soon.

== Additional resources from the international guideline community ==

=== Examples of disclosure of interest forms: ===
* [https://www.atsjournals.org/doi/full/10.1164/rccm.200901-0126ST#_i12 American Thoracic Society disclosure of interests form]
* [https://www.cadth.ca/sites/default/files/pcodr/pCODR%27s&#x20;Drug&#x20;Review&#x20;Process/pcodr-coi-guidelines-form.docx CADTH pan-Canadian Oncology Drug Review disclosure of interest form for panel members]
* [https://www.cadth.ca/sites/default/files/pcodr/pCODR%27s&#x20;Drug&#x20;Review&#x20;Process/pcodr-clinician_coi-declaration.docx CADTH pan-Canadian Oncology Drug Review disclosure of interest form for clinicians]
* [https://www.cadth.ca/sites/default/files/pcodr/pCODR%27s&#x20;Drug&#x20;Review&#x20;Process/pcodr-patientad-coi-declaratio.doc CADTH pan-Canadian Oncology Drug Review disclosure of interest form for patient groups]
* [https://canadiantaskforce.ca/wp-content/uploads/2020/10/COI-Policy-202008Final-1.pdf Canadian Task Force on Preventive Healthcare disclosure of interest form] (see Appendix 1)
* [https://community.cochrane.org/sites/default/files/uploads/EPPR/Cochrane-COI-disclosure-form.pdf Cochrane Collaboration disclosure of interest form]
* [https://www.uspto.gov/sites/default/files/documents/OGE450_June_2015.pdf US FDA financial disclosure report – Executive Branch]
* [https://www.fda.gov/media/70455/download US FDA financial disclosure report – Special Government Employees]
* [https://www.nationalacademies.org/coi/bi-coi_form-3.pdf National Academies of Science Engineering and Medicine disclosure of interest form for general scientific and technical studies and assistance]
* [https://www.nationalacademies.org/coi/bi-coi_form-2.pdf National Academies of Science Engineering and Medicine disclosure of interest form for studies involving program reviews and evaluations]
* [https://www.nationalacademies.org/coi/bi-coi_form-1.pdf National Academies of Science Engineering and Medicine disclosure of interest form for studies related to government regulation]
* National immunization technical advisory groups (NITAGs)
** [http://www.nitag-resource.org/uploads/media/default/0001/04/e80de42a64ee6f017cc42996b34a0cbb6e056ff0.pdf Initial COI declaration form]
** [http://www.nitag-resource.org/uploads/media/default/0001/04/e80de42a64ee6f017cc42996b34a0cbb6e056ff0.pdf COI annual update form]
** [http://www.nitag-resource.org/uploads/media/default/0001/04/e80de42a64ee6f017cc42996b34a0cbb6e056ff0.pdf COI declaration prior to a meeting]

* [https://www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-procedures/declaration-form.docx National Institute for Health and Care Excellence (UK) disclosure of interest form for advisory committees]
* [https://www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-procedures/declaring-and-managing-interests-board-and-employees.pdf National Institute of Health and Care Excellence (UK) disclosure of interest form for board members and employees]
* [https://www.sign.ac.uk/assets/delirium_pat_doi_form.pdf Scottish Intercollegiate Guideline Network (SIGN) disclosure of interest form for completion by individuals, carers, voluntary organisations and members of the public]
* [https://www.uspreventiveservicestaskforce.org/Page/Name/appendix-ii-uspstf-conflict-of-interest-disclosure-form United States Preventive Services Task Force (USPSTF) disclosure of interest form]

=== Examples of published summaries of disclosures ===
* [https://www.health.gov.au/sites/default/files/atagi-conflict-of-interest-disclosures.pdf Australian Technical Advisory Group on Immunisation disclosure summary]
* [https://www.has-sante.fr/jcms/sd_700659/fr/declaration-publique-d-interets Haute Authorité de Santé (France) examples of public disclosures of experts]

=== Examples of scales for assessing the significance of COI ===
* [https://www.atsjournals.org/doi/full/10.1164/rccm.200901-0126ST#_i13 American Thoracic Society method for evaluating significance of COI]
* [https://www.who.int/publications/guidelines/handbook_2nd_ed.pdf World Health Organization criteria for assessing the severity of a conflict of interest] (see p. 78)
* [https://www.sciencedirect.com/science/article/pii/S0749379717303768?via%3Dihub#t0015 USPSTF COI significance and management table]

=== Examples of algorithms/process maps for COI management ===
* [https://canadiantaskforce.ca/wp-content/uploads/2020/10/COI-Policy-202008Final-1.pdf Canadian Task Force on Preventive Healthcare algorithm for disclosure of interests and management of COI] (see Appendix 3)
* [https://www.atsjournals.org/doi/full/10.1164/rccm.200901-0126ST#_i14 American Thoracic Society COI resolution procedure]
* [https://cadth.ca/sites/default/files/pcodr/pCODR%27s&#x20;Drug&#x20;Review&#x20;Process/pcodr-coi-guidelines.pdf CADTH pan-Canadian Oncology Drug Review COI management overview] (Appendix A)
* [https://www.ema.europa.eu/en/documents/other/policy-44-european-medicines-agency-policy-handling-competing-interests-scientific-committees_en.pdf European Medicines Agency COI management matrix]
* [https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/ServicesSociaux/INESSS_Cadre_elaboration_guides_pratique_servicessociaux.pdf Institut national d’excellence en santé et en services sociaux (INESSS) diagramme de processus en matière de conflits d’intérêts] (Annexe D)
* [https://nrc.canada.ca/en/corporate/values-ethics/process-flowchart-nrc-conflict-interest-post-employment-policy National Research Council Canada COI flowchart]
* [https://www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-procedures/declaration-of-interests-policy.pdf National Institute of Health and Care Excellence (UK) process for declaring interests] (Appendix A)

=== [https://annals.org/aim/fullarticle/2450219/guidelines-international-network-principles-disclosure-interests-management-conflicts-guidelines GIN principles paper] ===

== References ==
<references />